|
시장보고서
상품코드
1806070
광학 유전체 매핑(OGM) 시장 규모, 점유율, 성장 분석, 제품별, 방법별, 최종 용도별, 컴포넌트별, 지역별 - 산업 예측(2025-2032년)Optical Genome Mapping Market Size, Share, and Growth Analysis, By Product (Instruments, Consumables & Reagents), By Technique (Structural Variant Detection, Genome Assembly), By End-Use, By Component, By Region - Industry Forecast 2025-2032 |
||||||
광학 유전체 매핑(OGM) 세계 시장 규모는 2023년에 1억 1,590만 달러로 평가되었습니다. 예측 기간(2025년-2032년) CAGR은 21.2%로, 2024년 1억 4,047만 달러에서 2032년까지는 6억 5,404만 달러로 성장할 전망입니다.
광학 유전체 매핑(OGM) 시장은 쇼트 리드 시퀀싱으로는 효과적으로 대응할 수 없는 복잡한 구조적 변이체를 안정적으로 식별하고자 하는 연구소가 증가함에 따라 크게 성장하고 있습니다. 시료 비용을 줄이면서 처리량을 향상시키는 화학 및 플로우 셀 기술의 혁신과 함께, 장비 배치 및 시약 대여 옵션의 확대로 접근성이 향상되고 있습니다. 벤더는 자동화, 클라우드 기반 분석, 표준화된 보고를 통해 워크플로우를 최적화하고 종양학, 혈액 악성 종양, 희귀질환, 세포 및 유전자 치료의 품질 관리에서 재현성을 촉진하고 있습니다. 연구 시험에서 광범위한 응용으로 채택이 확대됨에 따라, 초점은 소모품, 소프트웨어, 서비스로 옮겨가고 있습니다. 주요 동향으로는 OGM과 NGS의 하이브리드 보고, AI를 통한 변이체 콜링, 집중 분석 네트워크 구축 등이 있으며, OGM은 전 세계 바이오제약 및 연구소에 필수적인 유전체 특성 분석 도구로 자리매김하고 있습니다.
Global Optical Genome Mapping Market size was valued at USD 115.9 million in 2023 and is poised to grow from USD 140.47 million in 2024 to USD 654.04 million by 2032, growing at a CAGR of 21.2% during the forecast period (2025-2032).
The market for Optical Genome Mapping (OGM) is witnessing substantial growth as laboratories increasingly seek reliable identification of complex structural variants that short-read sequencing cannot effectively address. Enhanced access is driven by the expansion of instrument placements and reagent rental options, alongside innovations in chemistry and flow cell technology that boost throughput while reducing sample costs. Vendors are optimizing workflows through automation, cloud-based analysis, and standardized reporting, fostering reproducibility across oncology, hematologic malignancies, rare diseases, and cell-and-gene therapy quality control. As adoption broadens from research trials to widespread application, focus shifts towards consumables, software, and services. Key trends include hybrid OGM and NGS reporting, AI-driven variant calling, and the establishment of centralized analysis networks, solidifying OGM's position as a vital genome characterization tool for biopharma and laboratories worldwide.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Optical Genome Mapping market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Optical Genome Mapping Market Segments Analysis
Global Optical Genome Mapping Market is segmented by Product, Technique, End-Use, Component and region. Based on Product, the market is segmented into Instruments, Consumables & Reagents and Software and Services. Based on Technique, the market is segmented into Structural Variant Detection, Genome Assembly, Microbial Strain Typing and Rare Variant Identification. Based on End-Use, the market is segmented into Biotech & Pharma Companies, Hospitals & Clinical Labs, Academic Institutes and Contract Research Organizations (CROs). Based on Component, the market is segmented into Hardware and Software. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Optical Genome Mapping Market
The growth of the global optical genome mapping market is significantly driven by laboratories adopting comprehensive end-to-end processes that seamlessly integrate optical genome mapping with sequencing, allowing them to tackle complex genomic rearrangements effectively. The establishment of standardized pipelines, the use of reference samples, and the development of detailed interpretative guidelines enable consistent and reproducible results across various locations. Additionally, with larger patient cohorts and evolving reporting necessities, the frequency of repeat kit usage rises. The introduction of cloud-based analysis further accelerates turnaround times and enhances staff productivity, particularly for multi-site implementations, thereby fueling market expansion.
Restraints in the Global Optical Genome Mapping Market
The global optical genome mapping market faces several constraints, primarily due to the requirement for specialized expertise in triaging, classifying, and reporting structural variants. Smaller cohorts often encounter a steep learning curve related to analysis and quality control, with audit documentation adding to their workload. Without standardized cloud solutions and comprehensive standard operating procedures, inconsistencies between different sites can arise, which hampers operational efficiency and impedes the transition from research pilots to established service lines. Such challenges pose significant obstacles to the expansion and growth of the market, limiting its overall share in the industry.
Market Trends of the Global Optical Genome Mapping Market
The global Optical Genome Mapping (OGM) market is witnessing a notable trend towards hybrid solutions that combine OGM with sequencing technologies for comprehensive genome characterization. This integration facilitates enhanced detection of large genomic rearrangements alongside precise identification of breakpoints and variants, promoting a more nuanced understanding of genetic anomalies. The adoption of shared reporting pipelines and harmonized reference sets drives efficiency in analysis, reducing review cycles and increasing concordance among multidisciplinary teams in fields like oncology, hematology, and constitutional genetics. Such advancements not only enhance diagnostic accuracy but also foster collaborative decision-making, establishing a strong momentum for market growth.